A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
出版年份 2016 全文链接
标题
A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
作者
关键词
Antibody-dependent cell-mediated cytotoxicity, B-cell lymphoma, CD20, Chronic lymphocytic leukemia, Glycoengineering, Monoclonal antibody, Non-Hodgkin lymphoma, Obinutuzumab, Oncology, Rituximab
出版物
ADVANCES IN THERAPY
Volume 34, Issue 2, Pages 324-356
出版商
Springer Nature
发表日期
2016-12-21
DOI
10.1007/s12325-016-0451-1
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma
- (2016) Chia-Yen Lu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- New Strategies for the Treatment of Solid Tumors with CAR-T Cells
- (2016) Hao Zhang et al. International Journal of Biological Sciences
- Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma
- (2016) Nicole C. Smits et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
- (2016) Laurie H Sehn et al. LANCET ONCOLOGY
- Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies
- (2016) Capucine L. Grandjean et al. Scientific Reports
- Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) B. Eichhorst et al. ANNALS OF ONCOLOGY
- Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) H. Tilly et al. ANNALS OF ONCOLOGY
- Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions
- (2015) C. L. Freeman et al. BLOOD
- Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia
- (2015) J. C. Byrd et al. BLOOD
- Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial
- (2015) Jennifer R. Brown et al. BLOOD
- Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies
- (2015) T. R. W. Tipton et al. BLOOD
- Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma
- (2015) G. Cartron et al. HAEMATOLOGICA
- Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
- (2015) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study
- (2015) V Goede et al. LEUKEMIA
- Antibody modulation: Limiting the efficacy of therapeutic antibodies
- (2015) Andrew T. Vaughan et al. PHARMACOLOGICAL RESEARCH
- Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies
- (2015) Liping L. Sun et al. Science Translational Medicine
- Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers
- (2015) L Ysebaert et al. Blood Cancer Journal
- A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
- (2015) Eric J. Smith et al. Scientific Reports
- Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma
- (2015) G. Cartron et al. HAEMATOLOGICA
- Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody
- (2015) Valentin Goede et al. Oncology Research and Treatment
- Lymphoma Immunotherapy: Current Status
- (2015) Roberta Zappasodi et al. Frontiers in Immunology
- Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) M. Dreyling et al. ANNALS OF ONCOLOGY
- Inhibitory Fc RIIb and CD20 internalization
- (2014) I. Dransfield BLOOD
- Antibody-modified T cells: CARs take the front seat for hematologic malignancies
- (2014) M. V. Maus et al. BLOOD
- Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study
- (2014) G. Cartron et al. BLOOD
- Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?
- (2014) D. Grimwade et al. BLOOD
- Fc -receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments
- (2014) R. P. Taylor et al. BLOOD
- Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study
- (2014) Charles H Pritchard et al. BMC MUSCULOSKELETAL DISORDERS
- Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma?
- (2014) E. Bachy et al. CLINICAL CANCER RESEARCH
- New antibody approaches to lymphoma therapy
- (2014) Tejas Suresh et al. Journal of Hematology & Oncology
- Within Peripheral Blood Mononuclear Cells, Antibody-Dependent Cellular Cytotoxicity of Rituximab-Opsonized Daudi cells Is Promoted by NK Cells and Inhibited by Monocytes due to Shaving
- (2014) P. V. Beum et al. JOURNAL OF IMMUNOLOGY
- Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma
- (2014) Sean H. Lim et al. JOURNAL OF IMMUNOLOGY
- KIR/HLA Interactions Negatively Affect Rituximab- but Not GA101 (Obinutuzumab)-Induced Antibody-Dependent Cellular Cytotoxicity
- (2014) G. Terszowski et al. JOURNAL OF IMMUNOLOGY
- Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity
- (2014) S. Herter et al. JOURNAL OF IMMUNOLOGY
- Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma
- (2014) Shaker Dakhil et al. LEUKEMIA & LYMPHOMA
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy
- (2014) Monica Coughlan et al. CANCER IMAGING
- Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies
- (2014) Judith Trotman et al. Lancet Haematology
- Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)
- (2013) J. Radford et al. BLOOD
- Inhibitory Fc RIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity
- (2013) A. T. Vaughan et al. BLOOD
- Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience
- (2013) D. Tan et al. BLOOD
- The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab
- (2013) Eleanor J. Cheadle et al. BRITISH JOURNAL OF HAEMATOLOGY
- Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study
- (2013) Gilles A. Salles et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study
- (2013) Franck Andre Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- Recombinant Human IL-15 Trans-Presentation by B Leukemic Cells from Chronic Lymphocytic Leukemia Induces Autologous NK Cell Proliferation Leading to Improved Anti-CD20 Immunotherapy
- (2013) E. Laprevotte et al. JOURNAL OF IMMUNOLOGY
- Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties
- (2013) S. Rafiq et al. JOURNAL OF IMMUNOLOGY
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
- (2013) Mathias J Rummel et al. LANCET
- Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab
- (2013) Lina Reslan et al. LEUKEMIA & LYMPHOMA
- GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present
- (2013) Delila J. Kern et al. LEUKEMIA & LYMPHOMA
- Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma
- (2013) Frank Herting et al. LEUKEMIA & LYMPHOMA
- Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
- (2013) Christian Klein et al. mAbs
- Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics
- (2013) Josée Golay et al. mAbs
- Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
- (2013) S. Herter et al. MOLECULAR CANCER THERAPEUTICS
- Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies
- (2013) Mark Chao Cancer Management and Research
- ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
- (2012) M. Ghielmini et al. ANNALS OF ONCOLOGY
- Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway
- (2012) J. Honeychurch et al. BLOOD
- Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
- (2012) G. Salles et al. BLOOD
- A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies
- (2012) L. H. Sehn et al. BLOOD
- Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma
- (2012) Michinori Ogura et al. CANCER SCIENCE
- Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in
- (2012) V Goede et al. LEUKEMIA
- Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia
- (2012) Emilie Laprevotte et al. LEUKEMIA RESEARCH
- CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101
- (2011) M. Jak et al. BLOOD
- A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies
- (2011) K.-H. Heider et al. BLOOD
- The future of anti-CD20 monoclonal antibodies: are we making progress?
- (2011) W. Alduaij et al. BLOOD
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
- (2011) W. Alduaij et al. BLOOD
- Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
- (2011) G. Niederfellner et al. BLOOD
- Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy
- (2011) S. H. Lim et al. BLOOD
- Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
- (2011) L. Bologna et al. JOURNAL OF IMMUNOLOGY
- Loss of CD20 and Bound CD20 Antibody from Opsonized B Cells Occurs More Rapidly Because of Trogocytosis Mediated by Fc Receptor-Expressing Effector Cells Than Direct Internalization by the B Cells
- (2011) P. V. Beum et al. JOURNAL OF IMMUNOLOGY
- Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101
- (2011) S. Dalle et al. MOLECULAR CANCER THERAPEUTICS
- Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death
- (2010) J. Golay et al. BLOOD
- Response: novel lysosomal-dependent cell death following homotypic adhesion occurs within cell aggregates
- (2010) M. S. Cragg et al. BLOOD
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
- (2010) B. Coiffier et al. BLOOD
- Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells
- (2010) Michaela Patz et al. BRITISH JOURNAL OF HAEMATOLOGY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
- (2010) Gilles Salles et al. LANCET
- Long-Term Follow-Up of Patients With Newly Diagnosed Follicular Lymphoma in the Prerituximab Era: Effect of Response Quality on Survival—A Study From the Groupe d'Etude des Lymphomes de l'Adulte
- (2009) Emmanuel Bachy et al. JOURNAL OF CLINICAL ONCOLOGY
- Lymphoma in Adolescents and Young Adults
- (2009) Samantha M. Jaglowski et al. SEMINARS IN ONCOLOGY
- Complement and cellular cytotoxicity in antibody therapy of cancer
- (2008) Siao-Yi Wang et al. EXPERT OPINION ON BIOLOGICAL THERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started